Summary.-Forty-four (44) patients with Burkitt's lymphoma received identical combination chemotherapy on the basis of body surface area. Patients with renal dysfunction, more common in those with abdominal tumours, were at significantly greater risk of developing severe leucopenia (<1000 cells/dl) than those with normal renal function (P<0-0001). Similar results were seen in a series of 8 patients with normal marrows treated with only i.v. cyclophosphamide and intrathecal methotrexate. Giving a lower initial dose of cyclophosphamide seemed to reduce the risk of severe leucopenia in 5 additional patients with evidence of renal dysfunction. The mechanism is postulated as delayed excretion of the active metabolites of cyclophosphamide. Adjustment of the chemotherapeutic dose should be considered when treating patients with renal dysfunction.
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LEUCOPENIA is a common sequela of chemotherapy for malignant disease and may be the factor limiting the amount of chemotherapy tolerated. We have observed a distinct pattern to the degree of leucopenia seen in patients with Burkitt's lymphoma treated with the same protocol of combination chemotherapy: patients with abdominal tumours lhad leucopenia that was very significantly more severe than those without abdominal tumours. We attribute this difference largely to the higher incidence of renal dysfunction, overt or subelinical, in patients with abdominal tumours.
PATIENTS AND METHODS
The initial observations were evaluated by a review of the records of 44 consecutive patients with histologically or cytologically confirmed Burkitt's lymphoma -who met the evaluation criteria. In these patients, treatrnent consisted of 3 courses of cyclophosphamide (CP, 700 mg/M2) and vincristin (VN 1-4 mg/mn2) i.v., cytosine arabinoside (AraC 100 mg/m2/day, given q6H for 3 days) s.e. and 15 mg methotrexate (MTX) intrathecally. All patients were newly diagnosed and had received no prior chemotherapy. Allopurinol and i.v. fluids were also given to all patients during the first course of therapy and thereafter as clinically indicated. Following statistical verification of the observation by a review of existing records, further studies were undertaken on the next 13 patients with proven Burkitt lymphoma presenting for initial therapy. Details are given in the results.
Patients were classified only on the basis of whether abdominal tumours were detected. Extra-abdominal Burkitt's lymphoma may present at a variety of sites, of which facial is most common, and all but one patient wAithout abdominal disease had facial tumours. Marrow examination in the retrospective portion of the study wAas done when involvement was suspected. No patient writh known marrow involvement was included in the analysis. All patients in the prospective study had nmarrow! involvement excluded by examination of iliac-crest marrow aspiration. (Wright, 1964 (Krakoff & Murphy, 1968) . Whatever the aetiology, the renal dysfunction was often rapidly reversible following chemotherapy and by the 2nd course of therapy f-Linction was usually normal.
These findings suggest that a reduction in the initial course of chemotherapy for Burkitt's lymphoma might reduce the hazard of severe leucopenia, especially in patients with renal impairment. After the first course of therapy has significantly reduced tumour volume and renal function has improved, more intensive consolidation therapy would bebetter tolerated. Renal dysfunction has not been reported as being a significant factor in leucopenia associated with cyclophosphamide. If this association is confirmed, the hazard of severe leucopenia should be applicable to all cancer patients with renal dysfunction who are receiving this drug.
